Loading...
Loading...
Piper Jaffray reiterates its Neutral rating and $5 price target on Exelixis, Inc.
EXEL as company highlights plans to maximize its opportunity in castrate resistant prostate cancer.
Piper Jaffray comments, “Exelixis intends to conduct 2 pivotal CRPC studies with bone pain and overall survival (OS) data by 2014. Exelixis signed a CRADA with the NCI's Cancer Therapy Evaluation Program (CTEP), funding up to 20 clinical trials of cabozantinib for each of 5 years. We look for continued news and data flow on Cabo throughout 2012 including an NDA submission in metastatic thyroid cancer (MTC) in 1H:12 and full EXAM data likely at ASCO in June.”
EXEL closed at $4.54 per share on Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in